Electronic Aspirin Market Identifies the Key Drivers of Growth and Challenges of the Key Industry Players


The global electronic aspirin market is expected to witness considerable growth during the forecast period due to the increasing headache, stress related work and rise in demand for advanced medical devices. Electronic aspirin is a novel technology that aims to reduce pain in conditions such as migraines, cluster headaches and other head and facial pain. The key end user in the electronic aspirin market include hospitals, ambulatory surgical centers (ASCs) and others.
Aspirin is the most accepted brand available in the market for headache and pain and has been extended to be used for heart attack and stroke. Electronic aspirin relieves pain through nerve stimulated implantable device and is used to block the Sphenopalatine Ganglion Signals (SPG), which is a group of nerve cells associated with the trigeminal nerve and is characterized with the identification of headache disorders in humans. Electronic aspirin is implanted permanently in the upper gum on the side of head severely affected by headache. The implant tip will connect to the SPG bundle, whenever patient feels headache, the device would help through remote control for pain relief.

Request to Get the Sample Pages at:

Electronic aspirin is still under clinical development and seeking approval from the United States Food Drug and Administration (USFDA). In addition to increasing future expectation for electronic aspirin market is driven by, increasing prevalence of headaches, rising healthcare expenditure and high demand for advanced medical devices. In developed countries, increase investment in research and development will further boost the growth of electronic aspirin market.

Currently, only Autonomic Technologies Inc (ATI) is investing in the development of electronic aspirin. The company is mainly focusing on the development of new therapies for treatment of cluster headaches. For instance, in March 2017, ATI received an expanded indication (CE mark) in the Europe for the Pulsante SPG Microstimulator system to include pain relief for highly affected migraine patients. The Pulsante Microstimulator System provides on demand stimulation of the SPG, which is known for cluster headache and migraine. It is the first implantable neuro stimulation therapy to receive CE mark for headache and migraine related pain reliefs.

Comments

Popular posts from this blog

Hospital Bed Market by Type, Treatment, Geography – Market Size, Growth and Demand

How the Patient Handling Equipment Market Has Witnessed Substantial Growth in Coming Years?

Facial Skin Ablative Treatment Market To Reach $8,394.3 Million by 2030